Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04181294 · ClinicalTrials.gov registry record · NA

Time Limited Trials to Reduce Non-Beneficial Intensive Care Unit Treatments

A NA study of Critical Illness and Communication, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.

Completed
Registry status
NA
Development phase
209
Enrollment target
3
Study locations

NCT04181294: Completed NA study of Critical Illness and Communication, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.

NCT04181294 is a NA study of Critical Illness and Communication that has completed, run by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The registered enrollment target is 209 participants, below the 3,136-participant average among 91 other Critical Illness trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04181294, a NA study of Critical Illness and Communication, has completed, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.

COMPLETED
Registry status
NA
Development phase
209 participants
Enrollment target
3
Study locations

Study Summary

Overutilization of intensive care unit (ICU) treatments among patients with advanced medical illnesses and poor prognosis places them at risk for prolonged suffering with minimal anticipated benefit. Improving communication and shared decision-making between providers and patients/family members represents an opportunity to reduce potentially non-beneficial treatments. Time limited trials (TLTs) are agreements between clinicians and patients/surrogate decision-makers to use medical therapies over a defined period of time to observe if patients improve or deteriorate according to agreed-upon clinical outcomes. The objective of this project is to examine whether a quality improvement intervention that uses protocoled time limited trials as the default ICU communication/care planning strategy for patients with advanced medical illnesses will decrease the duration and intensity of non-beneficial ICU treatments without changing hospital mortality.

Primary Outcome

ICU LOS will be collected using the electronic medical record

Interventions

  • BEHAVIORAL Family meetings using time limited trials as default ICU communication and care planning approach
  • BEHAVIORAL Usual practice

Study Locations (3)

California

  • Los Angeles County-University of Southern California Medical Center - Los Angeles
  • Olive View Medical Center - Sylmar
  • Harbor UCLA Medical Center - Torrance

Trial Details

FieldValue
Enrollment Target 209 participants
Start Date 2017-08-01
Est. Completion 2019-12-31
Phase NA

What the finished NCT04181294 record still lists

NCT04181294 is an interventional study that assigns participants to a tested intervention. The registered 209 participants enrollment target is mid-sized for trials with a published cap, below the 3,136-participant average among 91 other Critical Illness trials with a reported enrollment target (93% lower).

The record links to 2 conditions, with Critical Illness appearing as the primary indexed condition, and to 2 interventions - of which Family meetings using time limited trials as default ICU communication and care planning approach is the first listed.

NCT04181294 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04181294 about?

NCT04181294 is a clinical study titled "Time Limited Trials to Reduce Non-Beneficial Intensive Care Unit Treatments". Overutilization of intensive care unit (ICU) treatments among patients with advanced medical illnesses and poor prognosis places them at risk for prolonged suffering with minimal anticipated benefit. Improving communication and shared decision-making between providers and patients/family members rep...

What is the current status of trial NCT04181294?

This trial is currently completed. It is a NA study. The enrollment target is 209 participants. The study started on 2017-08-01. Estimated completion is 2019-12-31.

What conditions does trial NCT04181294 study?

This clinical trial studies the following conditions: Critical Illness, Communication.

What interventions are being tested in trial NCT04181294?

The interventions under investigation include: Family meetings using time limited trials as default ICU communication and care planning approach (BEHAVIORAL), Usual practice (BEHAVIORAL).

Who is sponsoring clinical trial NCT04181294?

This trial is sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04181294 being conducted?

This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Critical Illness

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04181294's enrollment target sits among peer trials

209 48th of 91 higher than 43 of 91 other Critical Illness trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Critical Illness trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04742634 · 209 participants · Phase 1

    Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant

  • NCT07214688 · 209 participants · Phase 2

    Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies

  • NCT02665923 · 210 participants

    Gastric Emptying in Neonates and Infants After Formula Feeding

  • NCT03322891 · 210 participants · NA

    Improving Health Literacy in African-American Prostate Cancer Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04181294, the US trial registry maintained by the National Library of Medicine. NCT04181294 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.